Research programme: mast cell stabilisers - Bridge Pharma
Alternative Names: Mast cell stabilisers research programme - Bridge PharmaLatest Information Update: 28 May 2007
At a glance
- Originator Bridge Pharma
- Class
- Mechanism of Action Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 17 Jun 2002 Bridge Pharma and Immune Network have terminated their joint venture
- 26 Apr 2000 Preclinical development for Asthma in USA (PO)